- Home
- PDS vs PHVS Comparison
PDS vs PHVS Comparison
Compare PDS & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDS
- PHVS
- Stock Information
- Founded
- PDS 1951
- PHVS 2015
- Country
- PDS Canada
- PHVS Switzerland
- Employees
- PDS N/A
- PHVS N/A
- Industry
- PDS
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- PDS
- PHVS Health Care
- Exchange
- PDS Nasdaq
- PHVS Nasdaq
- Market Cap
- PDS 764.8M
- PHVS 1.3B
- IPO Year
- PDS N/A
- PHVS 2021
- Fundamental
- Price
- PDS $57.81
- PHVS $23.38
- Analyst Decision
- PDS Buy
- PHVS Strong Buy
- Analyst Count
- PDS 2
- PHVS 5
- Target Price
- PDS $87.00
- PHVS $35.60
- AVG Volume (30 Days)
- PDS 75.5K
- PHVS 123.8K
- Earning Date
- PDS 10-28-2025
- PHVS 11-12-2025
- Dividend Yield
- PDS N/A
- PHVS N/A
- EPS Growth
- PDS N/A
- PHVS N/A
- EPS
- PDS 5.22
- PHVS N/A
- Revenue
- PDS $1,355,177,217.00
- PHVS N/A
- Revenue This Year
- PDS N/A
- PHVS N/A
- Revenue Next Year
- PDS $1.37
- PHVS N/A
- P/E Ratio
- PDS $11.04
- PHVS N/A
- Revenue Growth
- PDS N/A
- PHVS N/A
- 52 Week Low
- PDS $36.20
- PHVS $11.51
- 52 Week High
- PDS $67.46
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- PDS 58.68
- PHVS 55.19
- Support Level
- PDS $55.85
- PHVS $23.20
- Resistance Level
- PDS $58.80
- PHVS $24.83
- Average True Range (ATR)
- PDS 1.47
- PHVS 1.34
- MACD
- PDS -0.11
- PHVS -0.02
- Stochastic Oscillator
- PDS 74.68
- PHVS 58.45
About PDS Precision Drilling Corporation
Precision Drilling Corp is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.